Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 April 1996 | Volume 124 Issue 7 | Pages 664-672
Objectives: 1] To determine the proportions of patients with visceral leishmaniasis who had various treatment outcomes when cared for under wartime conditions and with limited resources and 2) to identify patient characteristics associated with the outcomes.
Design: Cohort study.
Setting: Medicins sans Frontieres-Holland's treatment center in Duar, Western Upper Nile province, an area in southern Sudan that has been severely affected by Sudan's civil war and a massive epidemic of visceral leishmaniasis.
Patients: 3076 consecutive patients who had visceral leishmaniasis, were admitted to the treatment center the first year the center was operational (August 1990 to July 1991), and were treated with the pentavalent antimonial compound sodium stibogluconate.
Measurements: Patient characteristics on admission and four mutually exclusive treatment outcomes (default during first admission, death during first admission, discharge and readmission for retreatment [relapse], and discharge and no readmission for retreatment [successful treatment]).
Results: The patients had a median age of 15 years and were notably anemic (median hemoglobin level, 77 g/L) and malnourished (median body mass index of adults [more than equals 18 years of age], 15.2 kg/m2); most (91.0%) had been sick less than 5 months. Although patients could not be monitored after treatment to document cure, most (2562 [83.3%]) were successfully treated; 336 (10.9%) died during their first admission, and 79 are known to have relapsed (3.0% of those discharged alive [that is, those whose final treatment outcome was successful treatment or relapse]). In univariable analysis, young and older age (< 5 or more than equals 45 years of age), long duration of illness (
Conclusion: Despite the severe debility of the patients and the exceptionally difficult circumstances under which they were treated, most fared remarkably well.
Author and Article Information
From Medecins Sans Frontieres-Holland, Amsterdam, the Netherlands, and the Centers for Disease Control and Prevention, Atlanta, Georgia.
ABROAD
Epidemic Visceral Leishmaniasis in Southern Sudan: Treatment of Severely Debilitated Patients under Wartime Conditions and with Limited Resources
5 months), markedly low hemoglobin level or body mass index, large spleen, high parasite density, and vomiting at least once during the treatment course were associated with death. In multiple logistic regression analysis of data for a subgroup of 1207 adults (those who did not default or relapse and for whom data were recorded on age, sex, duration of illness, hemoglobin level, body mass index, and spleen size), the approximate risk ratios for death were 2.2 (95% CI, 1.4 to 3.6) for those with a long duration of illness, 3.6 (CI, 2.1 to 5.9) for those 45 years of age or older, 4.6 (CI, 2.2 to 9.4) for those with a hemoglobin level less than 60 g/L, and 12.2 (CI, 3.2 to 47.2) for those with a body mass index less than 12 kg/m2.
![]()
Acknowledgments: The authors thank Marga Goris for data entry; Allen W. Hightower for statistical advice; the Medecins Sans Frontieres-Holland expatriate staff and the Sudanese staff, especially Francis Galeak, who worked in the southern Sudan program; and especially the patients and their relatives, who showed remarkable resilience, courage, and dignity, despite tremendous adversity.
Requests for Reprints: Barbara L. Herwaldt, MD, MPH, Centers for Disease Control and Prevention, Division of Parasitic Diseases, Mailstop F-22, 4770 Buford Highway NE, Atlanta, GA 30341-3724.
Current Author Addresses: Dr. Seaman: Medecins Sans Frontieres-Holland, Box 40643, Nairobi, Kenya.
This article has been cited by other articles:
![]() |
R. J. Welch, B. L. Anderson, and C. M. Litwin Rapid Immunochromatographic Strip Test for Detection of Anti-K39 Immunoglobulin G Antibodies for Diagnosis of Visceral Leishmaniasis Clin. Vaccine Immunol., September 1, 2008; 15(9): 1483 - 1484. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Melaku, S. M. Collin, K. Keus, F. Gatluak, K. Ritmeijer, and R. N. Davidson Treatment of Kala-Azar in Southern Sudan using a 17-Day Regimen of Sodium Stibogluconate Combined with Paromomycin: A Retrospective Comparison with 30-Day Sodium Stibogluconate Monotherapy Am J Trop Med Hyg, July 1, 2007; 77(1): 89 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. B. DA SILVA, J. M. STEWART, and C. H. N. COSTA SENSITIVITY OF BONE MARROW ASPIRATES IN THE DIAGNOSIS OF VISCERAL LEISHMANIASIS Am J Trop Med Hyg, June 1, 2005; 72(6): 811 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Murray Kala-Azar -- Progress against a Neglected Disease N. Engl. J. Med., November 28, 2002; 347(22): 1793 - 1794. [Full Text] [PDF] |
||||
![]() |
S. Sundar and M. Rai Laboratory Diagnosis of Visceral Leishmaniasis Clin. Vaccine Immunol., September 1, 2002; 9(5): 951 - 958. [Full Text] [PDF] |
||||
![]() |
P. Probst, E. Stromberg, H. W. Ghalib, M. Mozel, R. Badaro, S. G. Reed, and J. R. Webb Identification and Characterization of T Cell-Stimulating Antigens from Leishmania by CD4 T Cell Expression Cloning J. Immunol., January 1, 2001; 166(1): 498 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.K. Jha, S. Sundar, C.P. Thakur, P. Bachmann, J. Karbwang, C. Fischer, A. Voss, and J. Berman Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis N. Engl. J. Med., December 9, 1999; 341(24): 1795 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Herwaldt Miltefosine -- The Long-Awaited Therapy for Visceral Leishmaniasis? N. Engl. J. Med., December 9, 1999; 341(24): 1840 - 1842. [Full Text] |
||||